300434.SZ
Sichuan Goldstone Asia Pharmaceutical, Inc.
SZSE · Industrials · C 制造业 · CN
CNY 11.27
−4.81%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- —
- EBIT
- +130.8%
- EPS
- +187.2%
- Free cash flow
- -24.2%
- Operating cash flow
- -18.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -5.8%
- EBITDA
- -12.7%
- EBIT
- -19.3%
- Net income
- -15.6%
- EPS
- -15.1%
- Free cash flow
- -26.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026